DBV Technologies SA, a clinical-stage biopharmaceutical company, has announced the sale of approximately $30 million of American Depositary Shares (ADSs) through its At-The-Market (ATM) program on Nasdaq. The new ordinary shares, issued in the form of ADSs, were sold to Artisan Partners Limited Partnership through Citizens Capital Markets as sales agent. This transaction will result in a dilution of approximately 5.96% for existing shareholders. Following this offering, the company estimates its cash runway is now extended to the end of the fourth quarter of 2026, providing sufficient funds to support operations for at least the next 12 months.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DBV Technologies SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001135835-en) on October 29, 2025, and is solely responsible for the information contained therein.
Comments